Teva Pharmaceutical Industries Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Teva Pharmaceutical Industries ha aumentado sus beneficios a una tasa media anual de 35.7%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 12.6% anual. Los ingresos han ido creciendo a una tasa media de 2.2% al año. La rentabilidad financiera de Teva Pharmaceutical Industries es de 9.1%, y sus márgenes netos son de 4.1%.
Información clave
35.66%
Tasa de crecimiento de los beneficios
35.72%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 5.95% |
| Tasa de crecimiento de los ingresos | 2.24% |
| Rentabilidad financiera | 9.11% |
| Margen neto | 4.08% |
| Última actualización de beneficios | 30 Jun 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Seeking Alpha • Aug 03
Teva's Re-Rating Still Has Room To Run
Summary Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026. I maintain a Buy rating, as TEVA still trades below sector multiples and further upside is possible if specialty growth and margin targets are met. Read the full article on Seeking Alpha
Actualización de narrativa • Jul 21
TEVA: Fairly Valued Outlook Will Weigh Vitiligo Data And Biosimilar Expansion
Analysts have lifted their fair value estimate for Teva Pharmaceutical Industries from about $21.53 to roughly $33.08, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples, along with recent price target increases across several firms and renewed confidence in the vitiligo program despite short term share price weakness. Analyst Commentary Recent commentary on Teva Pharmaceutical Industries has centered on how investors should think about valuation relative to execution risk, particularly around the vitiligo program and the timing of clinical milestones.
Actualización de narrativa • Jul 07
TEVA: Vitiligo Readout And Neuroscience Expansion Are Expected To Drive Upside
Analysts have raised their fair value estimate for Teva Pharmaceutical Industries from $45.00 to about $48.72, citing updated assumptions around revenue growth, profit margins, and future P/E. These changes align with a series of recent price target increases across the Street.
Actualización de narrativa • Jun 23
TEVA: Neuroscience Pivot And Vitiligo Readout Timing May Support 2026 Repricing
Teva Pharmaceutical Industries' analyst price target has been adjusted slightly to $40.90, with analysts pointing to recent stock underperformance tied to macro factors and updated vitiligo trial timelines, while maintaining underlying confidence in the pipeline and business fundamentals. Analyst Commentary Recent commentary on Teva Pharmaceutical Industries highlights a mix of optimism about the company’s pipeline execution and caution around near term headlines and timing.Artículo de análisis • Jun 21
Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback
Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after a recent share price pullback, with the stock closing at $31.48. Investors are assessing how the current valuation lines up with the company’s fundamentals. See our latest analysis for Teva Pharmaceutical Industries. The recent 7 day share price return, down 9.1%, and 1 month share price return, down 7.6%, contrast with a 1 year total shareholder return of 85.7% and 3 year total shareholder return above 3x. This suggests that...Actualización de narrativa • Jun 08
TEVA: Neuroscience Pipeline And Branded Shift May Support 2026 Multiple Reappraisal
Teva Pharmaceutical Industries' analyst price target has been adjusted from $40.27 to $41.27, as analysts factor in updated assumptions for revenue growth, profit margins and future P/E, supported by a series of recent price target increases from major research firms. Analyst Commentary Recent price target revisions for Teva Pharmaceutical Industries cluster tightly in favor of higher valuations, with several large firms, including JPMorgan, lifting their targets by between US$1 and US$6.Actualización de narrativa • May 25
TEVA: Focused R&D In Neuroscience And Immunology Will Support 2026 Multiple Reappraisal
Analyst price targets on Teva Pharmaceutical Industries have edged higher, with the updated fair value estimate moving from about $40.09 to $40.27 as analysts factor in recent target increases and their views on the company’s R&D focus, core therapeutic areas, biosimilars business, and capital deployment plans. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries points to a cluster of higher price targets, with several bullish analysts updating their models after discussions with management about research priorities, therapeutic focus, biosimilars, and capital deployment.Actualización de narrativa • May 04
TEVA: Neuroscience And Immunology Pipeline Will Drive 2026 Multiple Reappraisal
Analysts lifted the Teva Pharmaceutical Industries price target to $40.09 from $38.18, citing updated assumptions that point to higher revenue growth expectations, a slightly lower projected profit margin, and a higher future P/E multiple. This view is supported by recent research notes highlighting management's R&D focus, build out in core therapeutic areas, biosimilars vision, and capital deployment plans.Actualización de narrativa • Apr 16
TEVA: Neuroscience And Immunology R&D And Biosimilars Will Shape 2026 Reappraisal
Analysts have nudged their Teva Pharmaceutical Industries price targets higher, with the model fair value moving from $37.82 to $38.18. This change is supported by updated views on the company's R&D focus in neuroscience and immunology, its biosimilars plans, capital deployment, and the evolving outlook for partnered assets such as duvakitug.Nueva narrativa • Apr 09
Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine
Catalysts About Teva Pharmaceutical Industries Teva Pharmaceutical Industries develops and sells generic medicines, biosimilars and branded therapies across central nervous system, respiratory and immunology related diseases. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Apr 02
TEVA: Neuroscience And Immunology Pipeline Progress Will Shape 2026 R&D Reappraisal
Narrative Update on Teva Pharmaceutical Industries The analyst price target framework for Teva Pharmaceutical Industries has shifted modestly higher, with recent Street targets moving into the mid to high $30s and low $40s as analysts cite progress in R&D across neuroscience, immunology and biosimilars, improved capital structure and clearer long term EBITDA growth visibility. This comes even as the updated fair value estimate edges from $38.14 to $37.82 on slightly lower modeled revenue growth and profit margins, along with a marginally higher future P/E assumption.Actualización de narrativa • Mar 18
TEVA: 2026 Neuroscience And Immunology Pipeline Progress Will Drive Bullish Outlook
Teva Pharmaceutical Industries' analyst price target is modestly higher, with recent $1 to $9 upward revisions tied to analysts' expectations for R&D progress in neuroscience and immunology, a growing biosimilars presence, and stronger cash generation that supports a slightly richer forward P/E multiple. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries focus on how the pipeline, cash generation, and balance sheet shape both upside potential and execution risks.Actualización de narrativa • Mar 04
TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook
Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.Actualización de narrativa • Feb 18
TEVA: Affordable Medicines And 2026 R&D Progress Will Shape Medium Term Outlook
Narrative Update Overview The analyst price target for Teva Pharmaceutical Industries has been revised modestly higher to $37.95, with analysts pointing to updated fair value estimates, slightly adjusted discount rates, a new revenue growth outlook, and recent Street research highlighting potential pipeline catalysts and the appeal of affordable medicines heading into 2026. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme.Actualización de narrativa • Feb 04
TEVA: Affordable Medicines And 2026 Pipeline Milestones Will Shape Medium Term Outlook
Analysts have raised their price targets on Teva Pharmaceutical Industries into a tighter valuation range, with our fair value estimate moving from US$35.32 to US$36.77. They point to improving profit margin assumptions, a lower future P/E, and support from recent research highlighting the affordable medicines theme and potential pipeline catalysts into 2026.Actualización de narrativa • Jan 20
TEVA: Affordable Medicines And 2026 Pipeline Catalysts Should Support Re Rating
Narrative Update Analysts have lifted their price target range for Teva Pharmaceutical Industries toward the mid US$30s, reflecting updated assumptions on fair value, profit margins, and future P/E as they point to affordable medicines and potential R&D catalysts around 2026 as key drivers of sentiment. Analyst Commentary Recent street research points to a more constructive tone around Teva Pharmaceutical Industries, with higher price targets tied to its focus on affordable medicines and potential R&D catalysts around 2026.Actualización de narrativa • Jan 06
TEVA: Shares Will Hold Steady As Q3 Trends Support Balanced Outlook
Analysts have nudged their price target for Teva Pharmaceutical Industries higher to about US$24, citing recent Q3 pricing and volume trends for key drugs and consistent expectations for earnings across commercial-stage biopharma names. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$24 price target as a reflection of steadier execution on key drugs, with recent Q3 pricing and volume trends supporting their valuation framework.Actualización de narrativa • Dec 22
TEVA: Shares Will Trade Sideways As IRA Pricing Clarity Drives Relief Rally
Analysts have raised their fair value estimate for Teva Pharmaceutical Industries to approximately $32.77 from about $28.61, citing recent price target increases to the mid 20 dollar range, expectations for stable Q3 performance, and a potential relief rally tied to upcoming Austedo IRA pricing clarity. Analyst Commentary Recent Street research reflects a generally constructive stance on Teva, with price targets moving higher in anticipation of stable near term execution and clearer visibility on Austedo economics under the Inflation Reduction Act.Actualización de narrativa • Dec 08
TEVA: Shares Will Trade Sideways As Drug Pricing Clarity Supports Margins
Analysts have nudged their average price target for Teva Pharmaceutical Industries higher from approximately $27.90 to about $28.60, citing stable near term earnings expectations, improving profit margin assumptions, and a potential relief rally tied to clarity on Austedo pricing under the IRA framework. Analyst Commentary Bullish analysts highlight that recent price target increases reflect growing confidence in Teva's ability to execute on its turnaround strategy and sustain earnings stability, even as broader biopharma peers face mixed revisions.Actualización de narrativa • Nov 24
TEVA: Shares Will Rally As IRA Drug Pricing Clarity Approaches
Teva Pharmaceutical Industries' analyst price target has been raised modestly, with analysts citing improved key drug performance and potential relief as regulatory pricing clarity emerges. This reflects a shift from approximately $27.45 to $27.90 per share.Artículo de análisis • Nov 13
We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative
Shareholders appeared to be happy with Teva Pharmaceutical Industries Limited's ( NYSE:TEVA ) solid earnings report...Artículo de análisis • Nov 12
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) shares have been powering on, with...Actualización de narrativa • Nov 07
TEVA: Stock Will Gain Momentum As Key Drug Pricing Decision Nears
Analysts have increased their price target for Teva Pharmaceutical Industries by approximately $3, citing improved Q3 trends as well as positive expectations for key drug pricing and regulatory developments. Analyst Commentary Recent updates from Street research highlight both optimistic outlooks and ongoing risks for Teva Pharmaceutical Industries as analysts revise their expectations following Q3 performance and future drug pricing developments.Actualización de narrativa • Oct 23
Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries
Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.Actualización de narrativa • Oct 09
Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand
Teva Pharmaceutical Industries saw its analyst price target increase modestly from $23.89 to $24.22 per share. Analysts cite anticipated relief rallies and favorable prospects for the company's Austedo pricing strategy.Actualización de narrativa • Sep 25
Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand
As Teva Pharmaceutical Industries’ future P/E and revenue growth forecasts remain essentially unchanged, the consensus analyst price target is also largely flat, with a slight increase from $23.56 to $23.89. What's in the News UZEDY, Teva's long-acting injectable risperidone for schizophrenia, secured South Korean regulatory approval and has reached strong commercial milestones, recording $117 million in 2024 net sales and $95 million in the first half of 2025.
Nueva narrativa • Apr 23
Generics And Biosimilars Pipeline And Expansion Will Define Progress
The Pivot to Growth strategy targets revenue enhancement through product innovation, operational efficiency, and a sustainable generics business.Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Teva Pharmaceutical Industries. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 26 | 17,315 | 706 | 4,128 | 1,714 |
| 31 Mar 26 | 17,349 | 1,565 | 4,054 | 988 |
| 31 Dec 25 | 17,258 | 1,410 | 3,973 | 1,013 |
| 30 Sep 25 | 16,776 | 713 | 3,805 | 993 |
| 30 Jun 25 | 16,628 | -157 | 3,755 | 977 |
| 31 Mar 25 | 16,616 | -1,286 | 3,735 | 1,003 |
| 31 Dec 24 | 16,544 | -1,639 | 3,702 | 998 |
| 30 Sep 24 | 16,772 | -959 | 3,652 | 978 |
| 30 Jun 24 | 16,290 | -453 | 3,573 | 991 |
| 31 Mar 24 | 16,004 | -478 | 3,542 | 961 |
| 31 Dec 23 | 15,846 | -559 | 3,498 | 953 |
| 30 Sep 23 | 15,273 | -2,336 | 3,433 | 936 |
| 30 Jun 23 | 15,017 | -2,350 | 3,409 | 858 |
| 31 Mar 23 | 14,925 | -1,711 | 3,407 | 847 |
| 31 Dec 22 | 14,925 | -2,446 | 3,445 | 838 |
| 30 Sep 22 | 15,141 | -1,291 | 3,516 | 872 |
| 30 Jun 22 | 15,433 | -1,054 | 3,583 | 919 |
| 31 Mar 22 | 15,557 | -615 | 3,533 | 938 |
| 31 Dec 21 | 15,878 | 417 | 3,528 | 967 |
| 30 Sep 21 | 16,231 | 726 | 3,630 | 1,016 |
| 30 Jun 21 | 16,324 | -3,915 | 3,626 | 1,052 |
| 31 Mar 21 | 16,284 | -3,982 | 3,629 | 1,030 |
| 31 Dec 20 | 16,659 | -3,990 | 3,671 | 997 |
| 30 Sep 20 | 16,673 | -4,031 | 3,686 | 936 |
| 30 Jun 20 | 16,788 | 4 | 3,681 | 919 |
| 31 Mar 20 | 17,095 | -825 | 3,783 | 970 |
| 31 Dec 19 | 16,887 | -999 | 3,806 | 1,010 |
| 30 Sep 19 | 16,396 | -4,048 | 3,922 | 1,073 |
| 30 Jun 19 | 16,831 | -4,007 | 4,051 | 1,143 |
| 31 Mar 19 | 17,355 | -3,559 | 4,087 | 1,157 |
| 31 Dec 18 | 18,271 | -2,399 | 4,214 | 1,213 |
| 30 Sep 18 | 19,693 | -11,059 | 4,073 | 1,264 |
| 30 Jun 18 | 20,781 | -10,256 | 4,280 | 1,484 |
| 31 Mar 18 | 21,800 | -16,050 | 4,589 | 1,663 |
| 31 Dec 17 | 21,853 | -16,525 | 4,846 | 1,778 |
| 30 Sep 17 | 23,479 | -5,963 | 5,335 | 2,116 |
| 30 Jun 17 | 23,425 | -6,145 | 5,370 | 2,248 |
| 31 Mar 17 | 22,743 | 78 | 5,326 | 2,154 |
| 31 Dec 16 | 21,903 | 68 | 4,973 | 2,077 |
| 30 Sep 16 | 20,292 | 1,591 | 4,863 | 1,873 |
| 30 Jun 16 | 19,552 | 1,346 | 4,709 | 1,571 |
| 31 Mar 16 | 19,480 | 1,697 | 4,631 | 1,582 |
| 31 Dec 15 | 19,652 | 1,573 | 4,838 | 1,525 |
| 30 Sep 15 | 19,939 | 1,775 | 4,836 | 1,458 |
Ingresos de calidad: TEVA tiene una única gran pérdida de $1.7B que afecta a sus resultados financieros de los últimos 12 meses de 30th June, 2026.
Margen de beneficios creciente: TEVA pasó a ser rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: TEVA ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 35.7% al año.
Acelerando crecimiento: TEVA ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.
Beneficios vs. Industria: TEVA ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (1%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de TEVA (9.1%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/09 04:25 |
| Precio de las acciones al final del día | 2026/09/09 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Teva Pharmaceutical Industries Limited está cubierta por 44 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Balaji Prasad | Barclays |
| Glen Santangelo | Barclays |